安琪酵母(600298) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 3,794,177,570.05, representing an increase of 8.95% compared to the same period last year[3]. - Net profit attributable to shareholders was CNY 370,112,142.65, up 16.02% year-on-year[3]. - Basic earnings per share increased to CNY 0.43, reflecting a growth of 16.22% from the previous year[3]. - Net profit for Q1 2025 was ¥386,961,034.27, representing a 17.30% increase from ¥329,930,836.25 in Q1 2024[19]. - Earnings per share for Q1 2025 were ¥0.43, compared to ¥0.37 in Q1 2024, reflecting a 16.22% increase[20]. - The company's net profit for Q1 2025 was CNY 56,044,517.32, a decrease of 15.5% compared to CNY 66,291,262.35 in Q1 2024[30]. - Operating profit for Q1 2025 was CNY 59,535,517.07, down from CNY 68,034,490.45 in the same period last year, reflecting a decline of approximately 6.9%[30]. Cash Flow - The net cash flow from operating activities improved significantly, reaching CNY -254,204,269.87, a 61.44% increase compared to the previous year[3]. - Cash inflow from operating activities in Q1 2025 was ¥4,225,218,581.93, an increase from ¥3,686,904,437.13 in Q1 2024[22]. - The company's cash and cash equivalents decreased slightly to RMB 1.35 billion from RMB 1.38 billion, a decline of approximately 2.93%[12]. - Cash flow from operating activities in Q1 2025 was negative at CNY -298,682,429.39, slightly worse than the negative CNY -296,365,787.94 in Q1 2024[31]. - The net cash flow from financing activities for Q1 2025 was CNY -173,167,977.35, contrasting with a positive CNY 449,315,040.49 in Q1 2024[32]. - The company reported a net cash outflow from investing activities of CNY -245,491,536.96, compared to CNY -456,187,609.04 in the previous period[24]. - Investment activities generated a net cash flow of CNY -11,279,642.87 in Q1 2025, an improvement from CNY -55,241,739.87 in Q1 2024[31]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 22,401,664,103.95, a 3.08% increase from the end of the previous year[4]. - Current assets totaled RMB 10.04 billion, up from RMB 9.51 billion, indicating a growth of about 5.58%[13]. - Total liabilities reached RMB 10.63 billion, up from RMB 10.39 billion, which is an increase of about 2.30%[14]. - The total assets increased to CNY 16,025,528,727.43 as of March 31, 2025, compared to CNY 14,693,031,497.31 at the end of 2024, reflecting a growth of 9.1%[26]. - The total liabilities rose to CNY 8,008,992,132.99, up from CNY 6,753,515,867.85, indicating an increase of 18.5%[27]. - The total equity remained stable at approximately RMB 11.77 billion, with a slight decrease from RMB 11.74 billion[14]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 67,802[8]. - The largest shareholder, Hubei Angel Biotechnology Group Co., Ltd., held 38.07% of the shares, totaling 330,707,745 shares[9]. Investment and Expenses - Investment income surged by 59.36% year-on-year, primarily due to the disposal of a subsidiary[6]. - The company reported a significant reduction in financial expenses by 83.25%, attributed to increased foreign exchange gains during the reporting period[6]. - Research and development expenses for Q1 2025 were ¥137,004,716.96, slightly down from ¥144,443,397.45 in Q1 2024[19]. - The company's R&D expenses for Q1 2025 were CNY 69,318,539.12, a decrease from CNY 74,963,284.33 in Q1 2024[29].